Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (359)	4/9/2002 4:51:29 AM
From: Icebrg	Read Replies (2) \| Respond to of 1022

Answering my own question. It is CAT. From their website. Knoll (a subsidiary of Abbott) In August 1993, CAT and Knoll initiated a broad collaboration, giving Knoll the right to select up to six target antigens for which CAT would develop human antibody therapeutics. CAT receives fees, milestones and royalties on the successful development of products from this collaboration. CAT, in conjunction with Knoll, has isolated and optimised human monoclonal antibodies against the first two nominated targets, TNF alpha and Interleukin-12, and these antibodies are now in clinical trials (D2E7 and J695 respectively). The development of J695 involved the partnership of Knoll and the Genetics Institute (a research unit of Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products) together with CAT. In March 1999, Knoll selected a third target and extended its collaboration with CAT. The target is Interleukin-18 (a pro-inflammatory cytokine). A fourth research programme, focused on an as yet undisclosed therapeutic target, has since been initiated at CAT on behalf of Knoll.